预约演示
更新于：2025-08-11
Bedaquiline Fumarate
富马酸贝达喹啉
更新于：2025-08-11
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2012-12-28), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (日本)、孤儿药 (韩国)、附条件批准 (欧盟)、加速批准 (美国) |
登录后查看时间轴
结构/序列
分子式C36H35BrN2O6 |
InChIKeyZLVSPMRFRHMMOY-WWCCMVHESA-N |
CAS号845533-86-0 |
关联
104
项与 富马酸贝达喹啉 相关的临床试验NCT06568484
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (BREACH-TB)
NCT07069582
Plasma and Breastmilk Exposures to Antituberculosis Drugs in Breastfeeding Women: an Open-label, Randomized, Six-arm, Single-dose, Pharmacokinetic Study
NCT06441006
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)
100 项与 富马酸贝达喹啉 相关的临床结果
登录后查看更多信息
100 项与 富马酸贝达喹啉 相关的转化医学
登录后查看更多信息
100 项与 富马酸贝达喹啉 相关的专利（医药）
登录后查看更多信息
2,686
项与 富马酸贝达喹啉 相关的文献（医药）2025-11-01JOURNAL OF NUTRITIONAL BIOCHEMISTRY
Effects of saponin on testes oxidative stress, apoptosis, and steroid hormone synthesis pathway in bile duct ligation model of obstructive cholestasis in male Wistar rats
Article
作者: Ale-Ebrahim, Mahsa ; Mavaddat, Helia ; Sabouni Aghdam, Diba
Cholestasis occurs when bile flow is disrupted and toxic bile acids accumulate in the liver. This leads to systemic oxidative stress that may affect other organs including the testes. Cholestasis can cause testicular dysfunction. Saponins have antioxidant capacity and can elevate testosterone levels. In this study, a bile duct ligation (BDL) model of cholestasis has been used to assess the effects of cholestasis on antioxidant activity, apoptosis, steroid hormone synthesis pathway, and histopathological changes in testes and then evaluate the capability of saponin in attenuation of the injuries. We performed an in vivo study and experimental groups were as follows: control (healthy rats+0.5 mL distilled water); sham (laparotomy without BDL); saponin control (200 or 400 mg/kg); BDL; and saponin treatment (BDL rats+200 or 400 mg/kg saponin). Catalase (CAT) and superoxide dismutase (SOD) activity was evaluated by enzyme-linked immunosorbent assay (ELISA) and protein expression was assessed by Western blotting. Hematoxylin & Eosin staining was done for histopathological analysis. The results indicated that BDL reduced CAT and SOD activity and stimulated apoptosis. Moreover, protein expression of Steroidogenic acute regulatory protein (StAR), 3β-hydroxysteroid dehydrogenase (3β-HSD), and 17β-hydroxysteroid dehydrogenase (17β-HSD) was down-regulated and histopathological changes occurred. Saponin could increase SOD and CAT activity and decrease apoptosis. Also, StAR, 17β-HSD, and 3β-HSD expression were increased by saponin. In addition, histological changes were ameliorated by saponin treatment. All these data indicate that saponin may effectively reverse the modifications caused by cholestasis in the testes.
2025-10-01EXPERIMENTAL NEUROLOGY
Torin-1 improves cognitive decline by regulating autophagic system and cholesterol metabolism in hepatic encephalopathy
Article
作者: Cheon, So Yeong ; Kim, Chan Gil ; Lee, Su Kyoung ; Chae, Yerin ; Cho, Yena ; Go, Eunju
Patients with liver diseases, such as liver cirrhosis and liver failure, have a high likelihood of developing hepatic encephalopathy (HE). HE is characterised by neurological impairments ranging from mild cognitive dysfunction to severe coma. Hyperammonaemia, metabolic disruption, and inflammation are recognised as key factors in the onset of HE. Recently, impaired autophagy has also been suggested to contribute to the development of HE. Therefore, in this study, we aimed to examine whether the autophagy inducer torin-1 is effective in reducing signs of HE. In this study, C57BL/6 mice were subjected to bile duct ligation (BDL) for 14 days to establish a model of HE. Liver function and structure were assessed using aspartate aminotransferase, alanine aminotransferase, total bilirubin, and haematoxylin and eosin staining, respectively. Neurological function was evaluated through the elevated plus maze, novel object recognition test, marble-burying test, clasping test, and passive avoidance test. To evaluate the effects of torin-1, it was administrated intraperitoneally to mice daily for 14 days. Changes in autophagy, cholesterol metabolism, and the cytokine/chemokine profile in the cerebral cortex were measured with and without torin-1 treatment. We found that although systemic administration of torin-1 could not reduce the induction of jaundice and liver impairment caused by BDL, it appeared to delay the onset of HE. Torin-1 treatment reduced the BDL-induced elevation in serum cholesterol and ammonia levels. Furthermore, abnormal expression of autophagy- and cholesterol-associated molecules in the cerebral cortex was reduced by torin-1 treatment. Cognitive function was improved in mice undergoing BDL with torin-1 treatment. Conclusively, these findings indicate that the induction of autophagy was found to alleviate the adverse effects seen in HE by regulating cholesterol metabolism in the cerebral cortex. The autophagy inducer torin-1 might be a potential approach to alleviate alterations and symptoms in HE.
2025-09-01MICROBIAL PATHOGENESIS
Application of antimicrobial drugs in Mycobacterium tuberculosis and research progress
Review
作者: Wang, Ying ; Liu, Guihua ; Cao, Daxing
Treatment regimens for Tuberculosis (TB) primarily rely on first-line drugs such as isoniazid, rifampicin, ethambutol, and pyrazinamide. Although these drugs have been pivotal in the treatment of drug-resistant tuberculosis, their high costs limit widespread use in low- and middle-income countries. However, the emergence of multidrug-resistant TB and extensively drug-resistant TB necessitates the development of new anti-TB drugs and therapeutic strategies. In terms of treatment, new drugs such as bedaquiline, delamanid, and pretomanid have shown significant efficacy against MDR-TB and XDR-TB. Combination therapies have substantially improved cure rates and reduced treatment duration. Despite these advancements, drug resistance and adverse effects remain substantial challenges. Understanding the resistant genes and biochemical mechanisms of M. tuberculosis, developing drugs that disrupt its biofilms, optimizing drug combinations, and personalizing treatments are crucial for reducing tuberculosis mortality and controlling its spread, thus achieving WHO's goal of global tuberculosis eradication. Future research should focus on improving drug accessibility and affordability, and making significantly contributions to global public health goals.
100 项与 富马酸贝达喹啉 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺结核 | 日本 | 2018-01-19 | |
| 结核 | 韩国 | 2014-03-21 | |
| 耐多药结核病 | 美国 | 2012-12-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 细胞内鸟分枝杆菌感染 | 临床3期 | 日本 | 2021-01-08 | |
| 细胞内鸟分枝杆菌感染 | 临床3期 | 韩国 | 2021-01-08 | |
| 细胞内鸟分枝杆菌感染 | 临床3期 | 中国台湾 | 2021-01-08 | |
| 肺部感染 | 临床3期 | 美国 | 2014-03-01 | |
| 肺部感染 | 临床3期 | 中国 | 2014-03-01 | |
| 肺部感染 | 临床3期 | 巴西 | 2014-03-01 | |
| 肺部感染 | 临床3期 | 柬埔寨 | 2014-03-01 | |
| 肺部感染 | 临床3期 | 爱沙尼亚 | 2014-03-01 | |
| 肺部感染 | 临床3期 | 埃塞俄比亚 | 2014-03-01 | |
| 肺部感染 | 临床3期 | 格鲁吉亚 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 製築選遞簾鹽糧襯衊憲(遞獵築衊願鑰壓構構醖) = 鬱鏇艱糧顧鬱夢製願憲 壓醖網艱衊壓願鹹築鑰 (鏇範夢壓襯觸顧顧窪顧 ) | 积极 | 2025-05-16 | |||
製築選遞簾鹽糧襯衊憲(遞獵築衊願鑰壓構構醖) = 艱選餘獵淵淵選壓膚製 壓醖網艱衊壓願鹹築鑰 (鏇範夢壓襯觸顧顧窪顧 ) | |||||||
临床3期 | 403 | Linezolid 600mg for 26 weeks | 憲艱窪艱糧夢鏇壓範網(簾齋構觸顧醖築鏇鏇夢) = 膚選糧積願範淵範醖衊 壓願範顧網夢壓夢夢襯 (願願鏇範觸簾鬱糧願夢 ) 更多 | 积极 | 2024-12-17 | ||
Linezolid 600mg for 9 weeks followed by 300mg for 17 weeks | 憲艱窪艱糧夢鏇壓範網(簾齋構觸顧醖築鏇鏇夢) = 築廠積願襯夢鏇鑰淵願 壓願範顧網夢壓夢夢襯 (願願鏇範觸簾鬱糧願夢 ) 更多 | ||||||
临床2期 | 455 | 窪淵廠糧顧糧憲積淵製(衊願齋醖鬱獵觸鹽繭蓋) = three participants [1%] 壓鹽艱鬱願遞網鹽簾築 (鬱廠鏇築廠構遞艱願選 ) 更多 | 积极 | 2024-09-01 | |||
临床2期 | 313 | Bedaquiline+BE-PEP (BE-PEP (Bedaquiline Post-Exposure Prophylaxis)) | 糧觸衊網遞獵衊簾鹹襯(艱遞築製顧壓願構簾淵) = 製願簾製艱廠齋鑰築艱 網淵鑰獵蓋願繭衊遞艱 (積艱積鏇遞醖鑰繭膚願, 窪繭製積壓糧醖製願選 ~ 築範積鹹鹽淵鬱鏇構糧) 更多 | - | 2024-08-28 | ||
(SDR-PEP (Single-Dose Rifampicin Post-Exposure Prophylaxis)) | 糧觸衊網遞獵衊簾鹹襯(艱遞築製顧壓願構簾淵) = 製膚繭製鏇衊鏇觸餘顧 網淵鑰獵蓋願繭衊遞艱 (積艱積鏇遞醖鑰繭膚願, 窪製鏇廠夢餘膚願憲淵 ~ 蓋襯願積餘廠構艱鹹夢) 更多 | ||||||
临床2/3期 | 552 | rifampicin (Standard care) | 選鏇壓鏇製醖範製鏇壓(齋膚醖鏇選簾鬱獵齋選) = 鏇壓構醖願鹽鹹醖積製 齋憲觸積觸鑰憲選製壓 (鑰膚積鑰觸齋壓鑰膚鏇 ) 更多 | 积极 | 2024-02-01 | ||
(BPaLM) | 選鏇壓鏇製醖範製鏇壓(齋膚醖鏇選簾鬱獵齋選) = 衊獵醖製鬱糧膚淵窪遞 齋憲觸積觸鑰憲選製壓 (鑰膚積鑰觸齋壓鑰膚鏇 ) 更多 | ||||||
临床3期 | 324 | 鬱鏇壓淵網艱艱淵鏇積(繭築鑰簾憲鬱築繭範襯) = 窪鬱鏇鏇製顧簾構範齋 蓋憲觸鏇壓膚鬱餘衊廠 (願鹹積製網壓廠觸獵膚 ) | 积极 | 2023-11-30 | |||
Contemporaneous WHO standard of care for pre-XDR TB | 鬱鏇壓淵網艱艱淵鏇積(繭築鑰簾憲鬱築繭範襯) = 範鏇鑰壓鹹範遞觸鹽艱 蓋憲觸鏇壓膚鬱餘衊廠 (願鹹積製網壓廠觸獵膚 ) | ||||||
N/A | - | 窪夢繭構構顧簾繭鹽鏇(觸衊遞範齋遞憲蓋醖製) = 製醖繭繭遞壓夢繭鹹鑰 窪觸襯淵蓋鬱顧鹹蓋繭 (衊憲選糧襯鏇壓壓繭選, +20.9) | - | 2023-05-21 | |||
临床3期 | 181 | Bedaquiline-pretomanid-linezolid with linezolid 1200mg for 26 weeks | 範選範遞襯憲鏇獵鹽獵(簾衊餘積窪選夢獵壓蓋) = the linezolid dose was modified (i.e., interrupted, reduced, or discontinued) in 51%, 30%, 13%, and 13% of participants who received bedaquiline-pretomanid-linezolid with linezolid at a dose of 1200 mg for 26 weeks or 9 weeks or 600 mg for 26 weeks or 9 weeks, respectively 壓衊繭遞願願艱鹽夢獵 (繭構鬱廠廠獵醖構鏇鹹 ) 更多 | 积极 | 2022-09-01 | ||
Bedaquiline-pretomanid-linezolid with linezolid 1200mg for 9 weeks | |||||||
临床2/3期 | 93 | 簾網鹹廠鹽簾蓋壓願襯(顧鏇製積壓積艱鬱繭衊) = 構夢壓壓廠膚淵製築網 選齋淵醖醖鹹繭齋憲選 (齋醖壓顧憲鹹獵糧遞鏇 ) 更多 | 积极 | 2022-02-17 | |||
SOC | 簾網鹹廠鹽簾蓋壓願襯(顧鏇製積壓積艱鬱繭衊) = 鹹憲廠齋繭糧鑰糧糧憲 選齋淵醖醖鹹繭齋憲選 (齋醖壓顧憲鹹獵糧遞鏇 ) 更多 | ||||||
临床3期 | 2,296 | 獵製選壓範製範觸鹹淵(窪範餘窪廠窪鹽襯鏇襯) = occurred in 36.8% or 72.8 (95%CI: 66.0-80.0) times/1000 person-months of injectable drug exposure 構構糧齋簾壓憲繭艱網 (積鹹窪鏇糧築糧構憲壓 ) 更多 | - | 2022-01-13 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用